BIG PHARMA WATCH: BIG PHARMA DELAYS NEW DRUGS THAT COULD HELP PATIENTS TO BOOST PROFITS

Report Finds Several Brand Name Drug Companies Waiting to Introduce New Read More

CSRXP: GSK’S FLOVENT SCHEME DESIGNED TO SIDESTEP ACCOUNTABILITY FOR EGREGIOUS PRICE HIKES

Big Pharma Giant Switches Popular Brand Name Inhaler to Authorized Generic to Read More

DOSE OF REALITY: BIG PHARMA’S R&D INVESTMENTS DISCREDIT DOOM AND GLOOM INNOVATION RHETORIC

Report Finds Big Pharma Increased Spending on R&D in First Half of 2023, Read More

CSRXP: BIG PHARMA RINGS IN 2024 WITH EGREGIOUS PRICE HIKES ON HUNDREDS OF BRAND NAME PRESCRIPTION DRUGS

Big Pharma Maintains Business-as-Usual Approach to Price-Gouging Americans to Read More

DOSE OF REALITY: EXPERT WITNESS HIGHLIGHTS BIG PHARMA’S EGREGIOUS PRICING OF NEW WEIGHT LOSS DRUGS

Senate Testimony Underscores Staggering Potential Cost of High-Priced Weight Read More

CSRXP: BIG PHARMA DOUBLES DOWN ON EGREGIOUS PRICE HIKES OUTPACING INFLATION

Administration Announces Drug Makers Increased Prices Faster Than Rate of Read More